Intravenous arketamine for treatment-resistant depression: open-label pilot study
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
We aimed to analyze the efficacy and safety of arketamine, the R(-)-enantiomer of ketamine, for treatment-resistant depression (TRD) in humans. Open-label pilot trial, seven subjects with TRD received a single intravenous infusion of arketamine (0.5 mg/kg); primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) 24 h after. Mean MADRS dropped from 30.7 before infusion to 10.4 after one day, a mean difference of 20.3 points [CI 95% 13.6-27.0; p < 0.001]; dissociation was nearly absent. Arketamine might produce fast-onset and sustained antidepressant effects in humans with favorable safety profile, like previously reported with animals; further controlled-trials are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinically, an initial open-label pilot trial found that (R)-ketamine exerted significant antidepressant effects in seven individuals with TRD and, furthermore, was associated with few dissociative symptoms [42].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [42]
In the citing paper
“Arketamine (R(-)-ketamine, PCN-101) has demonstrated results in its first open-label study delivering single IV infusion to seven TRD patients [121].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [121]
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Self-citationFedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605 · cited 2×
“Another important aspect is the apparent lower incidence of psychotomimetic effects with arketamine than with other forms, and it might be explained by its lower potential to produce dopamine release and reduction of parvalbumin-positive neurons when compared with esketamine as demonstrated in animal studies [16, 31].”
ResultSingh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466
Pharmacology of Ketamine Isomers in Surgical Patients
White, P. F., Ham, J., Way, W. L., & Trevor, A. (1980) · Anesthesiology · doi:10.1097/00000542-198003000-00008 · Cited by 425
COMPARATIVE PHARMACOLOGY OF THE KETAMINE ISOMERS
WHITE, P. F., SCHÜTTLER, J., SHAFER, A., STANSKI, D. R., HORAI, Y., & TREVOR, A. J. (1985) · British Journal of Anaesthesia · doi:10.1093/bja/57.2.197 · Cited by 415
Vollenweider, F. X., Leenders, K. L., Øye, I., Hell, D., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00042-9 · Cited by 413
McGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373
R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357
Ketamine administration in depressive disorders: a systematic review and meta-analysis
Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., Micoulaud-Franchi, J.-A., Richieri, R., Courtet, P., Abbar, M., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3664-5 · Cited by 339
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., Lapidus, K., McGirr, A., Somogyi, A. A., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv124 · Cited by 226
Self-citationCorreia-Melo, F. S., Leal, G. C., Vieira, F., Jesus-Nunes, A. P., Mello, R. P., Magnavita, G., Caliman-Fontes, A. T., Echegaray, M. V. F., Bandeira, I. D., Silva, S. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.086 · Cited by 193
Self-citationKetamine and other glutamate receptor modulators for depression in adults
Caddy, C., Amit, B. H., McCloud, T. L., Rendell, J. M., Furukawa, T. A., McShane, R., Hawton, K., & Cipriani, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub2 · Cited by 174
An update on ketamine and its two enantiomers as rapid-acting antidepressants
Zhang, K., & Hashimoto, K. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1554434 · Cited by 132
Hashimoto, K., Kakiuchi, T., Ohba, H., Nishiyama, S., & Tsukada, H. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0692-7 · Cited by 127 · cited 1×
“Another important aspect is the apparent lower incidence of psychotomimetic effects with arketamine than with other forms, and it might be explained by its lower potential to produce dopamine release and reduction of parvalbumin-positive neurons when compared with esketamine as demonstrated in animal studies [16, 31].”
ResultLee, E. E., Della Selva, M. P., Liu, A., & Himelhoch, S. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.01.003 · Cited by 124
Han, Y., Chen, J., Zou, D., Zheng, P., Li, Q., Wang, H., Li, P., Zhou, X., Zhang, Y., Liu, Y., et al. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s117146 · Cited by 113
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults
McCloud, T. L., Caddy, C., Jochim, J., Rendell, J. M., Diamond, P. R., Shuttleworth, C., Brett, D., Amit, B. H., McShane, R., Hamadi, L., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011611.pub2 · Cited by 102
Zheng, W., Cai, D.-B., Xiang, Y.-Q., Zheng, W., Jiang, W.-L., Sim, K., Ungvari, G. S., Huang, X., Huang, X.-X., Ning, Y.-P., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.002 · Cited by 99
Yang, C., Han, M., Zhang, J.-C., Ren, Q., & Hashimoto, K. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.03.034 · Cited by 91 · cited 1×
“Findings from animal studies have suggested that the other enantiomer of ketamine, R(−)-ketamine, or arketamine, might have a longer lasting and more potent antidepressant effect than ketamine and esketamine [15–19], and without psychotomimetic effects [16, 20, 21].”
Brain morphological and functional features in cognitive subgroups of schizophrenia
Yasuda, Y., Okada, N., Nemoto, K., Fukunaga, M., Yamamori, H., Ohi, K., Koshiyama, D., Kudo, N., Shiino, T., Morita, S., et al. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12963 · Cited by 77
Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review
S Correia-Melo, F., C Argolo, F., Araújo-de-Freitas, L., Carneiro Gomes Leal, G., Kapczinski, F., L Lacerda, A., & C Quarantini, L. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s135623 · Cited by 43
Self-citationXu, Z., Reynolds, G. P., Yuan, Y., Shi, Y., Pu, M., & Zhang, Z. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw070 · Cited by 36
WHITE, D. C. (1985) · British Journal of Anaesthesia · doi:10.1093/bja/57.7.658 · Cited by 23
Esketamine nasal spray approved for treatment-resistant depression
Traynor, K. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz065 · Cited by 15 · cited 4×
“Different trials have shown that ketamine, and its S(+)-enantiomer, esketamine, can promote fast improvement of MDD, even in patients with treatment resistant depression (TRD) [1–13] leading to the recent FDA approval of intranasal esketamine for TRD [14].”
BackgroundInfluentialComment on a Word to the Wise About Intranasal Esketamine
Drevets, W. C., Singh, J. B., Hough, D., Daly, E. J., Popova, V., & Manji, H. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19070688 · Cited by 12
Cited by
Brain–gut–microbiota axis in depression: A historical overview and future directions
Chang, L., Wei, Y., & Hashimoto, K. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.02.004 · Cited by 377
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01093-2 · Cited by 271
“with (R)-ketamine showed antidepressant efficacy without dissociative effects [18].”
BackgroundKetamine: A tale of two enantiomers
Jelen, L. A., Young, A. H., & Stone, J. M. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959644 · Cited by 246
De Gregorio, D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 259
“On the other hand, some clinical data suggest that dissociation is neither necessary (Leal et al., 2020) nor sufficient (Williams et al., 2018) to account for ketamine’s efficacy.”
Chirality of New Drug Approvals (2013–2022): Trends and Perspectives
McVicker, R. U., & O’Boyle, N. M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02239 · Cited by 255
Metadata
- Authors
- Leal, G. C., Bandeira, I. D., Correia-Melo, F. S., Telles, M., Mello, R. P., Vieira, F., Lima, C. S., Jesus-Nunes, A. P., Guerreiro-Costa, L. N. F., Marback, R. F., Caliman-Fontes, A. T., Marques, B. L. S., Bezerra, M. L. O., Dias-Neto, A. L., Silva, S. S., Sampaio, A. S., Sanacora, G., Turecki, G., Loo, C., Lacerda, A. L. T., & Quarantini, L. C.
- Affiliations
- Universidade Federal da Bahia (BR)
- Yale University (US)
- Douglas Mental Health University Institute (CA)
- Black Dog Institute (AU)
- Universidade Federal de São Paulo (BR)
- Corresponding author
- Quarantini, Lucas C.
- ORCID
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2020-02-20
- Volume
- 271
- Issue
- 3
- Pages
- 577-582
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- OpenAlex
- W3007923795
- Cited by
- 257
- References
- 36
- Citations by year
- 2026: 10 · 2025: 28 · 2024: 58 · 2023: 35 · 2022: 49 · 2021: 45 · 2020: 31
- FWCI
- 24.12
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Funders
- Programa de Pesquisa para o SUS (003/2017)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine enantiomers, treatment-resistant depression, intravenous infusion, antidepressant efficacy, dissociation, Montgomery-Asberg Depression Rating Scale, drug safety
- MeSH terms
- Adult, Aged, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Infusions, Intravenous, Ketamine, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Remission Induction, Severity of Illness Index, Outcome Assessment, Health Care, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.